Nemaura Medical, Inc. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
registrant is attached as Exhibit 99.1 to this report and is
incorporated herein by reference. The registrant undertakes no
obligation to update this information, including any
forward-looking statements, to reflect subsequently occurring
events or circumstances.
furnished to Item 7 and shall not be deemed to be “filed” for
the purpose of Section 18 of the Securities Exchange Act of
1934, as amended or otherwise subject to the liabilities of
that section. This information will not be deemed an admission
as to the materiality of any information contained herein that
is required to be disclosed solely by Regulation FD.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Corporate Presentation
|
About Nemaura Medical, Inc. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. Nemaura Medical, Inc. (OTCMKTS:NMRD) Recent Trading Information
Nemaura Medical, Inc. (OTCMKTS:NMRD) closed its last trading session up +0.25 at 3.00 with 300 shares trading hands.
